UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.508

Sortiert nach

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Journal of clinical oncology, 2018-04, Vol.36 (11), p.1080-1087

2018

Volltextzugriff (PDF)

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

Journal of clinical oncology, 2019-05, Vol.37 (15), p.1296-1304

2019

Volltextzugriff (PDF)

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Annals of oncology, 2018-04, Vol.29 (4), p.959-965

2018

Volltextzugriff (PDF)

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

The Lancet (British edition), 2019-05, Vol.393 (10184), p.1948-1957

2019

Volltextzugriff (PDF)

Shape of Nanoparticles as a Design Parameter to Improve Docetaxel Antitumor Efficacy

Bioconjugate chemistry, 2018-04, Vol.29 (4), p.1302-1311

2018

Volltextzugriff (PDF)

Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs

Biochimica et biophysica acta. Reviews on cancer, 2021-01, Vol.1875 (1), p.188481, Article 188481

Rizzo, Milena

2021

Volltextzugriff (PDF)

Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer

Drug resistance updates, 2024-03, Vol.73, p.101063-101063, Article 101063

2024

Volltextzugriff (PDF)

Micelles with ultralow critical micelle concentration as carriers for drug delivery

Nature biomedical engineering, 2018-05, Vol.2 (5), p.318

2018

Volltextzugriff (PDF)

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

The lancet oncology, 2019-10, Vol.20 (10), p.1395-1408

2019

Volltextzugriff (PDF)

Dendronized hyaluronic acid-docetaxel conjugate as a stimuli-responsive nano-agent for breast cancer therapy

Carbohydrate polymers, 2021-09, Vol.267, p.118160, Article 118160

2021

Volltextzugriff (PDF)

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

The Lancet (British edition), 2019-01, Vol.393 (10167), p.156-167

2019

Volltextzugriff (PDF)

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

The lancet oncology, 2018-11, Vol.19 (11), p.1468-1479

2018

Volltextzugriff (PDF)

Deep Penetration of Nanolevel Drugs and Micrometer-Level T Cells Promoted by Nanomotors for Cancer Immunochemotherapy

Journal of the American Chemical Society, 2021-08, Vol.143 (31), p.12025-12037

2021

Volltextzugriff (PDF)

An improved LC–MS/MS method for determination of docetaxel and its application to population pharmacokinetic study in Chinese cancer patients

Biomedical chromatography, 2020-08, Vol.34 (8), p.e4857-n/a

2020

Volltextzugriff (PDF)

AS1411 aptamer/RGD dual functionalized theranostic chitosan-PLGA nanoparticles for brain cancer treatment and imaging

Biomaterials Advances, 2024-06, Vol.160, p.213833-213833, Article 213833

2024

Volltextzugriff (PDF)

High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme

ACS nano, 2019-02, Vol.13 (2), p.1365-1384, Article acsnano.8b06842

2019

Volltextzugriff (PDF)

Distinction Between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy

Langmuir, 2018-12, Vol.34 (50), p.15343-15349

2018

Volltextzugriff (PDF)

Redox-responsive nanoparticles based on Chondroitin Sulfate and Docetaxel prodrug for tumor targeted delivery of Docetaxel

Carbohydrate polymers, 2021-03, Vol.255, p.117393, Article 117393

2021

Volltextzugriff (PDF)

NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway

Cancer science, 2024-02, Vol.115 (2), p.412-426

2024

Volltextzugriff (PDF)

LncRNA LINC00184 promotes docetaxel resistance and immune escape via miR-105-5p/PD-L1 axis in prostate cancer

Immunobiology (1979), 2022-01, Vol.227 (1), p.152163-152163, Article 152163

2022

Volltextzugriff (PDF)

Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)

Breast cancer research and treatment, 2023-09, Vol.201 (2), p.193-204

2023

Volltextzugriff (PDF)

Unleashing a safe and potent pro-senescence anti-tumor strategy

Cancer cell, 2024-04, Vol.42 (4), p.504-507

2024

Volltextzugriff (PDF)

Cancer cell membrane-coated nanoparticles for bimodal imaging-guided photothermal therapy and docetaxel-enhanced immunotherapy against cancer

Journal of nanobiotechnology, 2021-12, Vol.19 (1), p.449-449, Article 449

2021

Volltextzugriff (PDF)

1 – 25 von 1.508

Suche als RSS-Feed

Aktive Filter

SpracheNorwegisch

ThemaDocetaxel

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.415)
Mit Volltextzugriff
(1.348)

Publikationsform

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.329)
Humans
(1.278)
Life Sciences & Biomedicine
(1.214)
Male
(703)
Oncology
(698)
Docetaxel - Therapeutic Use
(578)
Female
(578)
Chemotherapy
(499)
Middle Aged
(470)
Aged
(467)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(430)
Docetaxel - Administration & Dosage
(343)
Treatment Outcome
(308)
Docetaxel - Pharmacology
(305)
Adult
(286)
Prostate Cancer
(282)
Cell Line, Tumor
(258)
Patients
(245)
Cancer Therapies
(242)
Metastasis
(241)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Scientific Reports
(42)
Journal Of Clinical Oncology
(39)
Gan To Kagaku Ryoho
(35)
Bmc Cancer
(25)
Anticancer Research
(24)
British Journal Of Cancer
(22)
Clinical Cancer Research
(21)
Breast Cancer Research And Treatment
(19)
Annals Of Oncology
(18)
The Prostate
(17)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Shape of Nanoparticles as a Design Parameter to Improve Docetaxel Antitumor Efficacy

Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs

Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

Micelles with ultralow critical micelle concentration as carriers for drug delivery

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

Dendronized hyaluronic acid-docetaxel conjugate as a stimuli-responsive nano-agent for breast cancer therapy

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Deep Penetration of Nanolevel Drugs and Micrometer-Level T Cells Promoted by Nanomotors for Cancer Immunochemotherapy

An improved LC–MS/MS method for determination of docetaxel and its application to population pharmacokinetic study in Chinese cancer patients

AS1411 aptamer/RGD dual functionalized theranostic chitosan-PLGA nanoparticles for brain cancer treatment and imaging

High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme

Distinction Between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy

Redox-responsive nanoparticles based on Chondroitin Sulfate and Docetaxel prodrug for tumor targeted delivery of Docetaxel

NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway

LncRNA LINC00184 promotes docetaxel resistance and immune escape via miR-105-5p/PD-L1 axis in prostate cancer

Unleashing a safe and potent pro-senescence anti-tumor strategy

Cancer cell membrane-coated nanoparticles for bimodal imaging-guided photothermal therapy and docetaxel-enhanced immunotherapy against cancer

Aktive Filter

Suchergebnisse filtern